- Home
- AVPT vs QURE Comparison
AVPT vs QURE Comparison
Compare AVPT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | QURE |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | Netherlands |
| Employees | 3443 | 248 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AVPT | QURE |
|---|---|---|
| Price | $14.27 | $21.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $16.81 | ★ $61.24 |
| AVG Volume (30 Days) | 1.9M | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $21.81 | $54.78 |
| Revenue Next Year | $20.37 | $356.14 |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.84 | $8.73 |
| 52 Week High | $15.43 | $71.50 |
Technical Indicators
Market Signals| Indicator | AVPT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 23.34 |
| Support Level | $12.36 | $21.21 |
| Resistance Level | $14.39 | $25.61 |
| Average True Range (ATR) | 0.58 | 1.45 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.35 | 30.95 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.